Home » Newsletters » BioWorld

BioWorld

Oct. 1, 2007

View Archived Issues

Stock Winners and Losers For The Week

U.S. Public Offering Performance By Underwriter: January 1 August 31, 2007*

ALL OFFERINGS, ALL UNDERWRITERS, RANKED BY AFTER-MARKET PERFORMANCE*

UNDERWRITERS' PERFORMANCE ON IPOS: FULL CREDIT TO LEAD UNDERWRITER, RANKED BY AFTER-MARKET PERFORMANCE

IPOS: FULL CREDIT TO ALL UNDERWRITERS, RANKED BY GROSS PROCEEDS*

IPOS: FULL CREDIT TO ALL UNDERWRITERS,RANKED BY AFTER-MARKET PERFORMANCE*

PERFORMANCE ON ALL PUBLIC OFFERINGS: FULL CREDIT TO ALL UNDERWRITERS, RANKED BY GROSS PROCEEDS*

PERFORMANCE ON ALL PUBLIC OFFERINGS: FULL CREDIT TO ALL UNDERWRITERS, RANKED BY AFTER-MARKET PERFORMANCE

Quest For New Sleep Drugs Bearing Fruit, Inspiring Deals

Money Raised By Month

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 24, 2026.
Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s
BioWorld Science
Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...
4D Nucleome opens new wave of gene regulation research, discovery
BioWorld
After a decade of research, the NIH 4D Nucleome program on July 23 delivered a wealth of new insights into how spatial changes in chromatin structure and DNA...
Transcripta Bio raises funding to advance neuro pipeline
BioWorld Science
Transcripta Bio Inc. has raised $24 million since its series A to fund IND-enabling studies across its portfolio and support clinical preparation in its autism...
Daybu readthrough in EU? Zevra’s NPC bid flounders
BioWorld
Zevra Therapeutics Inc. will try to follow in the footsteps of Acadia Pharmaceuticals Inc. with Rett syndrome drug Daybu (trofinetide) by asking the EMA’s...